INT133422

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 10
Disease Relevance 4.90
Pain Relevance 1.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IL6ST) extracellular region (IL6ST) plasma membrane (IL6ST)
Anatomy Link Frequency
B cells 1
melanocyte 1
IL6ST (Homo sapiens)
Pain Link Frequency Relevance Heat
abatacept 5 97.24 Very High Very High Very High
Inflammation 150 96.88 Very High Very High Very High
rheumatoid arthritis 169 92.68 High High
cytokine 81 92.36 High High
Arthritis 42 73.24 Quite High
methotrexate 100 70.80 Quite High
depression 2 65.72 Quite High
Pain 13 40.40 Quite Low
metalloproteinase 10 26.00 Quite Low
chemokine 9 20.76 Low Low
Disease Link Frequency Relevance Heat
Synovitis 2 98.20 Very High Very High Very High
INFLAMMATION 178 96.88 Very High Very High Very High
Melanoma 29 94.60 High High
Rheumatoid Arthritis 172 92.68 High High
Cancer 71 90.72 High High
Disease 129 88.56 High High
Necrosis 16 86.48 High High
Leukemia 6 82.24 Quite High
Arthritis 33 73.24 Quite High
Dementia 16 71.60 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This complex can then bind gp130, which is expressed on a much wider variety of cell types.
gp130 Binding (bind) of
1) Confidence 0.40 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.47 Pain Relevance 0.19
This binding subsequently inhibits dimerization of the IL-6/IL-6R complex with membrane-bound gp130, preventing signaling.
gp130 Binding (bound) of
2) Confidence 0.31 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.35 Pain Relevance 0.13
However, in order to transduce a signal, the combination of IL-6/IL-6R must also bind a ubiquitous transmembrane protein, glycoprotein (gp) 130 (CD130).
CD130 Binding (bind) of
3) Confidence 0.30 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.61 Pain Relevance 0.18
which subsequently recruits and binds the GP130 subunit, dimerizes and forms an active high affinity complex (Bilinski et al., 1998).
GP130 Binding (dimerizes) of
4) Confidence 0.17 Published 2010 Journal Molecular Human Reproduction Section Body Doc Link PMC2816169 Disease Relevance 0.08 Pain Relevance 0.05
which subsequently recruits and binds the GP130 subunit, dimerizes and forms an active high affinity complex (Bilinski et al., 1998).
GP130 Binding (binds) of
5) Confidence 0.17 Published 2010 Journal Molecular Human Reproduction Section Body Doc Link PMC2816169 Disease Relevance 0.08 Pain Relevance 0.05
In this respect, the blocking of IL-6 receptor with tocilizumab, the prevention of costimulatory T cell signals by abatacept, or targeting B cells with rituximab look promising in clinical trials.
IL-6 receptor Binding (blocking) of in B cells associated with abatacept
6) Confidence 0.12 Published 2006 Journal Wien Med Wochenschr Section Abstract Doc Link 16465614 Disease Relevance 0.71 Pain Relevance 0.39
IL-6 forms a complex by binding to IL-6 R on the cell membrane, which then combines with gp130, which also resides on the cell membrane, forming a homodimer and giving rise to intracellular signal transduction.
gp130 Binding (combines) of
7) Confidence 0.11 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727785 Disease Relevance 0.40 Pain Relevance 0.24
IL-6 and IL-6 receptor form the IL-6/IL-6 receptor complex, which after binding to gp130 transmits its biological signal to the cell.
gp130 Binding (binding) of
8) Confidence 0.10 Published 2007 Journal Immun Ageing Section Body Doc Link PMC1845171 Disease Relevance 0.55 Pain Relevance 0.09
Newer drugs will include interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor ?
gp130 Binding (include) of
9) Confidence 0.10 Published 2007 Journal Immun Ageing Section Body Doc Link PMC1845171 Disease Relevance 0.81 Pain Relevance 0.17
The gp100 TAA is a melanocyte lineage-specific membrane glycoprotein consisting of 661 amino acids, categorized as a differentiation Ag.
membrane glycoprotein Binding (lineage) of in melanocyte
10) Confidence 0.02 Published 2010 Journal J Transl Med Section Body Doc Link PMC2949666 Disease Relevance 0.84 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox